Check out TNGN. They have a tiny market cap but Celgene just made another investment into the company. I believe this is the second time Celgene put money into the company. Additionally, institutions have started to purchase shares. The stock is undervalued considering the amount of cash they now have and the fact that CELG backs them
NVIV - they are doing some really interesting work in spinal cord injuries. Human trials are about to start and they are preparing to up-list to either NASDAQ or NYSE in the very near future. Good for a short-term or a long-term play IMO. Or both.
How about a company that long ago worked with AVI?......Exelixis
They have one drug, cabozinitib, that can be used for 15 different cancer types and is already on the market since January for medullary thyroid cancer. That means they've recently run the FDA gauntlet, and this very same drug can be used for many other indications!